CannEpil® is a phyto medicine based on phytocannabinoids currently investigated for the treatment of refractory epilepsy. Produced from two proprietaries, preselected, specifically bred genotypes of the cannabis plant with a stable and specific ratio of cannabinoids.
The first medicinal cannabis product eligible for patients in Ireland and fully covered under Ireland's Primary Care Reimbursement Service as part of the country's Medicinal Cannabis Access Programme (MCAP).
Available to prescribe in Australia and UK as an Investigational Medicinal Product through early patient access schemes.
MGC’s first pharmaceutical-grade product currently investigated for drug-resistant (refractory) epilepsy, which accounts for approximately 25% of the people diagnosed with epilepsy.
Information provided could come from a third-party source, and likely does not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).
About Argent BioPharma Ltd.
Changing lives with plant-based medicines. We are a bio-pharma company utilising the medical value of phytocannabinoids to provide relief to people suffering across the globe.
Founded in 2015, MGC Pharma aims to provide patients with the highest standard of phytomedicines in order to improve the quality of life for millions across the globe.
Our vision is to have a global impact on undertreated medical conditions and diseases, using the power of plant-based medicine in novel combinations by using technology to harness knowledge and science to achieve our “Nature to Medicine” strategy.
argentbiopharma.com
Further National Health-Service Information on